SPDRÂ S&PÂ Biotech ETF (XBI) ETF
Data as of September 4, 2026
Stockbruh grade: Challenging 0/3 metrics rated Sunny
What does SPDRÂ S&PÂ Biotech ETF invest in?
🧬 Looking to invest in biotechnology? Our fun and vibrant fund seeks to track the performance of the S&P Biotechnology Select Industry Index. We invest in securities from the index, which represents the exciting world of biotech.
Key Numbers
| Metric | Rating | What it means |
|---|
| Returns (5Y CAGR) | ⛅ Moderate | ≥8% = Sunny, 1–8% = Cloudy, <1% = Thunderstorm |
| Dividends | ⛅ Moderate | Dividend yield and consistency |
| Fees (Expense Ratio) | ⛅ Moderate | <0.5% = Sunny, 0.5–1.5% = Cloudy, >1.5% = Thunderstorm |
| Price | $164.38 | Assets Under Management | — |
Common Questions
How have XBI's returns been over the last 5 years?
XBI has delivered moderate 5-year returns (1%–8% CAGR), rated Cloudy on Stockbruh's weather system. Sign up to see the full return history.
Is XBI a good ETF for beginners?
Stockbruh provides a beginner-friendly analysis of XBI covering returns (5Y CAGR), dividend yield, and expense ratio. XBI has moderate fees. Sign up free to see the full weather-rated breakdown.